Trexquant Investment LP Buys Shares of 153,098 Genmab A/S (NASDAQ:GMAB)

Trexquant Investment LP bought a new stake in Genmab A/S (NASDAQ:GMAB) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 153,098 shares of the company’s stock, valued at approximately $4,875,000.

Other institutional investors have also recently added to or reduced their stakes in the company. Headlands Technologies LLC acquired a new stake in Genmab A/S in the third quarter valued at approximately $27,000. Pinnacle Bancorp Inc. lifted its stake in shares of Genmab A/S by 315.8% in the fourth quarter. Pinnacle Bancorp Inc. now owns 840 shares of the company’s stock worth $27,000 after buying an additional 638 shares during the last quarter. NBC Securities Inc. acquired a new stake in shares of Genmab A/S in the third quarter worth $37,000. Principal Securities Inc. acquired a new stake in shares of Genmab A/S in the fourth quarter worth $77,000. Finally, Advisors Preferred LLC acquired a new stake in shares of Genmab A/S in the fourth quarter worth $82,000. 7.07% of the stock is currently owned by institutional investors and hedge funds.

Genmab A/S Stock Performance

Shares of NASDAQ:GMAB opened at $29.81 on Thursday. Genmab A/S has a 52 week low of $26.32 and a 52 week high of $42.72. The company’s fifty day moving average is $29.36 and its 200-day moving average is $29.93. The company has a market capitalization of $19.71 billion, a PE ratio of 24.84, a P/E/G ratio of 1.06 and a beta of 1.00.

Analyst Ratings Changes

GMAB has been the subject of a number of analyst reports. HC Wainwright restated a “buy” rating and issued a $50.00 price objective on shares of Genmab A/S in a research note on Monday. BMO Capital Markets upgraded shares of Genmab A/S from a “market perform” rating to an “outperform” rating and boosted their price objective for the stock from $46.00 to $48.00 in a research note on Friday, February 23rd. Truist Financial reaffirmed a “buy” rating and set a $50.00 target price on shares of Genmab A/S in a research report on Tuesday, March 26th. Finally, Morgan Stanley reaffirmed an “underweight” rating on shares of Genmab A/S in a research report on Tuesday, March 26th. Three research analysts have rated the stock with a sell rating, two have given a hold rating and eight have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $48.50.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.